Table 2.

Recommendations by European Consensus Group [75]
Patients with ACS, AF and low/intermediate bleeding risk (bare metal /drug eluting stent)
Until 6 months- triple therapy (warfarin (INR 2.0–2.5) + aspirin =100 mg/day + clopidogrel 75 mg/day)
6-12 months – warfarin (INR 2.0–2.5) + clopidogrel 75 mg/day* (or aspirin 100 mg/day and then
Lifelong – (INR 2.0–3.0) alone
Patients with ACS, AF and high bleeding risk (bare metal stent only)
Until 4 weeks – triple therapy of warfarin (INR 2.0–2.5) + aspirin =100 mg/day +clopidogrel 75 mg/day
1-12 months -combination of warfarin (INR 2.0–2.5) + clopidogrel 75 mg/day*(or aspirin 100 mg/day); mg/day) and then
lifelong: warfarin (INR 2.0–3.0) alone.
Recommendations of North American Consensus Group [77]
Low stroke risk (CHADS2=0) and any stent thrombosis or bleeding risk
BMS – Dual antiplatelet therapy with aspirin and clopidogrel or prasugrel for one month and preferably for 12 months
DES – Dual antiplatelet therapy with aspirin and clopidogrel or prasugrel for 12 months or longer
Moderate/high stroke risk (CHADS2>1), low stent thrombosis risk and low bleeding risk
BMS – Triple therapy for at least one month then oral anticoagulation (OAC) + single antiplatelet (AP) for 12 months
DES – Triple therapy for at least six months then OAC +single AP for 12 months
Moderate/high stroke risk and high stent thrombosis risk and low bleeding risk
BMS -Triple therapy for at least six months then OAC +single AP for 12 months
DES – Triple therapy for 12 months